Neogenomics Inc
NASDAQ:NEO
Neogenomics Inc
Revenue
Neogenomics Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Neogenomics Inc
NASDAQ:NEO
|
Revenue
$610.7m
|
CAGR 3-Years
10%
|
CAGR 5-Years
15%
|
CAGR 10-Years
24%
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Revenue
$42.9B
|
CAGR 3-Years
10%
|
CAGR 5-Years
12%
|
CAGR 10-Years
13%
|
|
Danaher Corp
NYSE:DHR
|
Revenue
$43.7B
|
CAGR 3-Years
21%
|
CAGR 5-Years
21%
|
CAGR 10-Years
9%
|
|
Mettler-Toledo International Inc
NYSE:MTD
|
Revenue
$3.8B
|
CAGR 3-Years
7%
|
CAGR 5-Years
5%
|
CAGR 10-Years
5%
|
|
Agilent Technologies Inc
NYSE:A
|
Revenue
$6.7B
|
CAGR 3-Years
7%
|
CAGR 5-Years
6%
|
CAGR 10-Years
8%
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Revenue
$15B
|
CAGR 3-Years
10%
|
CAGR 5-Years
8%
|
CAGR 10-Years
11%
|
See Also
What is Neogenomics Inc's Revenue?
Revenue
610.7m
USD
Based on the financial report for Mar 31, 2024, Neogenomics Inc's Revenue amounts to 610.7m USD.
What is Neogenomics Inc's Revenue growth rate?
Revenue CAGR 10Y
24%
Over the last year, the Revenue growth was 15%. The average annual Revenue growth rates for Neogenomics Inc have been 10% over the past three years , 15% over the past five years , and 24% over the past ten years .